RU2015115898A - Новый вирус mva и его применения - Google Patents
Новый вирус mva и его применения Download PDFInfo
- Publication number
- RU2015115898A RU2015115898A RU2015115898A RU2015115898A RU2015115898A RU 2015115898 A RU2015115898 A RU 2015115898A RU 2015115898 A RU2015115898 A RU 2015115898A RU 2015115898 A RU2015115898 A RU 2015115898A RU 2015115898 A RU2015115898 A RU 2015115898A
- Authority
- RU
- Russia
- Prior art keywords
- amino acid
- gene product
- acid sequence
- mva virus
- gene
- Prior art date
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 102
- 241001183012 Modified Vaccinia Ankara virus Species 0.000 claims abstract 40
- 108090000623 proteins and genes Proteins 0.000 claims abstract 33
- 101150096528 A9L gene Proteins 0.000 claims abstract 31
- 101150085281 A3L gene Proteins 0.000 claims abstract 30
- 238000012986 modification Methods 0.000 claims abstract 28
- 230000004048 modification Effects 0.000 claims abstract 28
- 101150049392 A34R gene Proteins 0.000 claims abstract 24
- 230000035772 mutation Effects 0.000 claims abstract 21
- 150000007523 nucleic acids Chemical group 0.000 claims abstract 19
- 108091028043 Nucleic acid sequence Proteins 0.000 claims abstract 15
- 241000700605 Viruses Species 0.000 claims abstract 6
- 241000700618 Vaccinia virus Species 0.000 claims abstract 2
- 150000001413 amino acids Chemical class 0.000 claims 21
- 101100350652 Vaccinia virus (strain Western Reserve) VACWR122 gene Proteins 0.000 claims 6
- 101150115056 A31R gene Proteins 0.000 claims 5
- 102220603448 Homeobox protein SIX3_A34R_mutation Human genes 0.000 claims 5
- 101100000228 Vaccinia virus (strain Western Reserve) VACWR157 gene Proteins 0.000 claims 5
- 230000002209 hydrophobic effect Effects 0.000 claims 5
- 102220311820 rs1376867262 Human genes 0.000 claims 5
- 102220005376 rs33915947 Human genes 0.000 claims 5
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 102000039446 nucleic acids Human genes 0.000 claims 4
- 238000006467 substitution reaction Methods 0.000 claims 4
- 238000012258 culturing Methods 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 101150048714 75 gene Proteins 0.000 claims 2
- 238000002955 isolation Methods 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 230000037430 deletion Effects 0.000 claims 1
- 238000012217 deletion Methods 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000006801 homologous recombination Effects 0.000 claims 1
- 238000002744 homologous recombination Methods 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 102220179791 rs752964419 Human genes 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24061—Methods of inactivation or attenuation
- C12N2710/24064—Methods of inactivation or attenuation by serial passage
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Virology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2012/069256 WO2014048500A1 (en) | 2012-09-28 | 2012-09-28 | Novel mva virus and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2015115898A true RU2015115898A (ru) | 2016-11-20 |
Family
ID=46982581
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2015115898A RU2015115898A (ru) | 2012-09-28 | 2012-09-28 | Новый вирус mva и его применения |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US9732325B2 (enExample) |
| EP (1) | EP2900810B1 (enExample) |
| JP (1) | JP2015535687A (enExample) |
| CN (1) | CN104812894B (enExample) |
| AU (1) | AU2012391162A1 (enExample) |
| BR (1) | BR112015006798A2 (enExample) |
| CA (1) | CA2885240A1 (enExample) |
| DK (1) | DK2900810T3 (enExample) |
| IN (1) | IN2015DN02335A (enExample) |
| MX (1) | MX2015003687A (enExample) |
| RU (1) | RU2015115898A (enExample) |
| WO (1) | WO2014048500A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11104884B2 (en) | 2017-02-23 | 2021-08-31 | Probiogen Ab | Vaccinia virus vectors related to MVA with extensive genomic symmetries |
| JP7551496B2 (ja) | 2017-10-31 | 2024-09-17 | カリヴィル イムノセラピューティクス， インコーポレイテッド | 全身送達のためのプラットフォーム腫瘍溶解性ベクター |
| CN108371715A (zh) * | 2018-01-03 | 2018-08-07 | 肖小林 | 一种病毒的靶向性防治药物 |
| JP2021535730A (ja) * | 2018-05-11 | 2021-12-23 | シティ・オブ・ホープCity of Hope | 複数の部位メガロウイルス（ｃｍｖ）抗原の発現のためのｍｖａベクター及びその使用 |
| CN112384615A (zh) | 2018-07-04 | 2021-02-19 | 普罗拜奥根股份公司 | 用于纯化包膜病毒的方法 |
| WO2022109133A1 (en) | 2020-11-19 | 2022-05-27 | Kalivir Immunotherapeutics, Inc. | Oncolytic immunotherapy by tumor micro-environment remodeling |
| WO2023128672A1 (ko) * | 2021-12-29 | 2023-07-06 | 재단법인 아산사회복지재단 | 외피외 바이러스 생산이 증가한 신규한 백시니아 바이러스 변이주 |
| WO2023223183A1 (en) | 2022-05-16 | 2023-11-23 | Crispr Therapeutics Ag | Picornaviral vectors for gene editing |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7645456B2 (en) | 2001-04-23 | 2010-01-12 | Sanofi Pasteur Biologics Co. | Vaccinia virus strains |
| WO2005048957A2 (en) | 2003-02-20 | 2005-06-02 | Therion Biologics Corporation | Novel insertion sites in pox vectors |
-
2012
- 2012-09-28 US US14/431,814 patent/US9732325B2/en active Active
- 2012-09-28 JP JP2015533460A patent/JP2015535687A/ja active Pending
- 2012-09-28 WO PCT/EP2012/069256 patent/WO2014048500A1/en not_active Ceased
- 2012-09-28 EP EP12769398.4A patent/EP2900810B1/en active Active
- 2012-09-28 MX MX2015003687A patent/MX2015003687A/es unknown
- 2012-09-28 CA CA2885240A patent/CA2885240A1/en not_active Abandoned
- 2012-09-28 CN CN201280077370.4A patent/CN104812894B/zh active Active
- 2012-09-28 DK DK12769398.4T patent/DK2900810T3/en active
- 2012-09-28 BR BR112015006798A patent/BR112015006798A2/pt not_active IP Right Cessation
- 2012-09-28 IN IN2335DEN2015 patent/IN2015DN02335A/en unknown
- 2012-09-28 AU AU2012391162A patent/AU2012391162A1/en not_active Abandoned
- 2012-09-28 RU RU2015115898A patent/RU2015115898A/ru not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| DK2900810T3 (en) | 2019-04-29 |
| IN2015DN02335A (enExample) | 2015-08-28 |
| CN104812894A (zh) | 2015-07-29 |
| WO2014048500A1 (en) | 2014-04-03 |
| US9732325B2 (en) | 2017-08-15 |
| CA2885240A1 (en) | 2014-04-03 |
| MX2015003687A (es) | 2015-06-15 |
| JP2015535687A (ja) | 2015-12-17 |
| BR112015006798A2 (pt) | 2017-11-21 |
| EP2900810A1 (en) | 2015-08-05 |
| EP2900810B1 (en) | 2019-02-20 |
| CN104812894B (zh) | 2021-10-22 |
| US20150299666A1 (en) | 2015-10-22 |
| AU2012391162A1 (en) | 2015-04-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2015115898A (ru) | Новый вирус mva и его применения | |
| EP2529010B1 (en) | Vaccinia virus mutants containing the major genomic deletions of mva | |
| DK2367944T3 (en) | PROMOTERS FOR RECOMBINANT VIRAL EXPRESSION | |
| JP2015119730A5 (enExample) | ||
| JP2010259446A5 (enExample) | ||
| RU2014129788A (ru) | Вакцины против hpv | |
| Meisinger-Henschel et al. | Introduction of the six major genomic deletions of modified vaccinia virus Ankara (MVA) into the parental vaccinia virus is not sufficient to reproduce an MVA-like phenotype in cell culture and in mice | |
| JP2013507935A5 (enExample) | ||
| PH12020552197A1 (en) | Influenza virus hemagglutinin mutants | |
| CN107709554A (zh) | 重组经修饰痘苗病毒安卡拉(mva)口蹄疫病毒(fmdv)疫苗 | |
| CA2372709C (en) | Vector for integration of heterologous sequences into poxviral genomes | |
| JP6235697B2 (ja) | 変異ワクシニアウイルス株、その使用およびそれを作製する方法 | |
| RU2014129220A (ru) | Новый аттенуированный полиовирус: pv-1 mono-cre-x | |
| CN1723285A (zh) | 重组的mva及其产生方法 | |
| US11104884B2 (en) | Vaccinia virus vectors related to MVA with extensive genomic symmetries | |
| CA2815727A1 (en) | Modulation of immune responses by the poxviral k4 protein | |
| CN104975043A (zh) | 构建重组mva病毒的带有标记基因自删除系统的穿梭载体 | |
| KR101677231B1 (ko) | 무혈청배지（serum free medium）를 이용한 메갈로사이티바이러스의 효율적 제조방법 | |
| CN109504643B (zh) | 整合四拷贝功能性f18菌毛操纵子基因的益生菌克隆株、构建方法及应用 | |
| Kan et al. | Generation of an attenuated Tiantan vaccinia virus by deletion of the ribonucleotide reductase large subunit | |
| CN102851293B (zh) | 靶向抑制羊痘病毒ORF095基因的序列siRNA-165 | |
| JP2019187249A (ja) | 増殖性ヘルパーワクシニアウイルスを使用するポックスウイルスの製造方法 | |
| CN102796740B (zh) | 靶向抑制羊痘病毒ORF095基因的序列siRNA-70 | |
| CN102417907B (zh) | 靶向抑制羊痘病毒ORF095基因的siRNA序列 | |
| RU2016145253A (ru) | Химерный белок, синтетическая днк, кодирующая указанный белок, экспрессионный вектор, штамм-продуцент синтетической днк и способ получения плазмидной днк |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20150929 |